Publication: 3790

Local-regional recurrence following neoadjuvant endocrine therapy: Data from ACOSOG Z1031 (Alliance), a randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–positive clinical stage 2 to 3 breast cancer
      QxMD      Google Scholar   
Citation:
Ann Surg Oncol vol 30 (4) 2111-2118
Year:
2023
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
12
Parents:
3171  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
CTI BioPharma Corp, Pfizer, Novartis  
Grants:
U10CA180821, U10CA180882, U24CA196171, UG1CA233253, UG1CA233329, UG1CA233302, UG1CA232760; R01-CA095614, U01-CA114722  
Corr. Author:
 
Authors:
                   
Networks:
GA005, LAPS-MN026, LAPS-TX011, LAPS-TX035, TX041, TX190   
Study
ACOSOG-Z1031
Multiple Studies, or Legacy Studies in Alliance Study:
Alliance-A011106
Phases:
3, 3
Keywords:
Article